Pfizer's Flat Sales Outlook Amid Pipeline Rebuild

about 1 month ago

Lisa Mateo

"Yes. Fizer, PFE, their shares have been up as much as half a percent or so. Uh it forecasts little to no sales growth next year. Uh the company's trying to rebuild that drug pipeline, right? It has a number of acquisitions. The demand for CO shots have been fading. Um if you want the specifics, revenue 2026 is going to be 59.5 billion to 62.5 billion. And that was about in line with estimates. And sales this year, they're expected uh to be about 62 billion."

The Pfizer commentary provides a snapshot of the company's modest performance, with flat sales growth forecasts and ongoing efforts to rebuild its drug pipeline through acquisitions. The revenue expectations for 2026 and current year are in line with estimates, suggesting a neutral to mixed view on the stock.

Related Stocks